Canadian Journal of Infectious Diseases & Medical Microbiology最新文献

{"title":"A Novel Machine Learning Approach for Predicting Prognosis of SFTS Patients in the Early Stages of Disease.","authors":"Siqi Li, Ting Wang, Rujia Chen, Yun Wang, Renren Ouyang, Wei Wei, Feng Wang, Shiji Wu, Hongyan Hou","doi":"10.1155/cjid/5389795","DOIUrl":"10.1155/cjid/5389795","url":null,"abstract":"<p><strong>Objective: </strong>Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease characterized by high morbidity and mortality rates. Timely detection and prognosis prediction are critical for implementing effective clinical interventions. This study aimed to develop a binary classification machine learning model utilizing early clinical and laboratory indicators to predict the prognosis of SFTS patients, facilitating early clinical decision-making.</p><p><strong>Methods: </strong>We conducted a retrospective study including 233 SFTS patients diagnosed from October 2021 to May 2024. Clinical and laboratory data at initial diagnosis were collected and subjected to baseline analysis and correlation analysis to identify significant indicators. Using the area under the receiver operating characteristic curve as an indicator of model performance, select the analytical model among machine learning (LR) models, XGBOOST, LightGBM, and random forest. A binary classification machine learning model for predicting survival outcomes was constructed using a logistic regression algorithm in conjunction with identified metrics. The model's performance was evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV). The model was externally validated using a separate cohort of 73 patients.</p><p><strong>Result: </strong>A total of 233 patients were included in this study, among whom 146 (62.7%) survived and 87 (37.3%) died, with 208 assigned to the internal cohort (177 to the training set and 31 to the test set) and the external validation cohort consisted of 73 patients, including 52 survivors (71.2%) and 21 mortality cases (28.8%). Based on the AUC, the LR model (0.750) is selected, where the values of XGBOOST, LightGBM, and random forest are 0.649, 0.661, and 0.716, respectively. The logistic regression model, incorporating age, lactate dehydrogenase (LDH), albumin, activated partial thromboplastin time (APTT), and platelet count, demonstrated robust predictive accuracy with an AUC of 0.913 (95% CI: 0.821-1.000) for the test set and 0.923 (95% CI: 0.842-1.000) for the external validation set. The model exhibited an accuracy of 0.863, with a sensitivity of 0.952 and an NPV of 0.977. The specificity and PPV were 0.827 and 0.690, respectively. These results indicate that the model maintains robust discriminative performance in an independent cohort, suggesting its potential utility as a screening tool with high sensitivity and favorable NPV.</p><p><strong>Conclusion: </strong>The model constructed using the first diagnostic indicators described above can accurately determine the patient's prognosis, which can help the clinician intervene earlier as well as take the necessary life-saving measures, and has the potential to improve the survival rate of SFTS patients.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2026 ","pages":"5389795"},"PeriodicalIF":2.4,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148363900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic Effects of Amikacin With Imipenem and Ciprofloxacin Against Multidrug-Resistance Uropathogenic <i>Escherichia coli</i>.","authors":"Sahar Sadr Moharerpour, Fatemeh Ahmadi Parviji, Kasra Javadi, Mehrdad Halaji","doi":"10.1155/cjid/3283079","DOIUrl":"10.1155/cjid/3283079","url":null,"abstract":"<p><strong>Introduction: </strong>There are limited therapeutic options available for treating aminoglycoside- and carbapenem-resistant Gram-negative bacteria. Therefore, there is an urgent need for novel effective antimicrobial agents. Numerous studies have reported the enhanced efficacy of antibiotic combinations against multidrug-resistant (MDR) strains compared to monotherapy. This study aimed to investigate the potential synergistic effects of amikacin in combination with imipenem and ciprofloxacin against clinical isolates of MDR <i>Escherichia coli</i> to identify the most promising antibiotic combinations for treating infections caused by these isolates.</p><p><strong>Methods: </strong>In this experimental study, 20 MDR <i>E. coli</i> isolates were examined. The minimum inhibitory concentration (MIC) and checkerboard method were determined for amikacin, imipenem, and ciprofloxacin.</p><p><strong>Results: </strong>MIC determination revealed ciprofloxacin MICs of 4-512 μg/mL, imipenem 0.125-32 μg/mL, and amikacin 1-128 μg/mL. Resistance rates were 55% (11/20) for amikacin, 100% (20/20) for ciprofloxacin, and 55% (11/20) for imipenem. Synergistic effects were observed between amikacin and imipenem in 50% of isolates (10/20) and between amikacin and ciprofloxacin in 40% (8/20), with no antagonistic interactions detected.</p><p><strong>Conclusions: </strong>The combination of amikacin with imipenem or ciprofloxacin resulted in synergistic and additive effects in some cases. These findings suggest that antibiotic combination therapy could serve as an effective strategy in managing infections caused by antibiotic-resistant isolates.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2026 ","pages":"3283079"},"PeriodicalIF":2.4,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13288045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148320292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioactive Profiling of <i>Achillea millefolium</i> L. Growing in Kashmir: A Study on Its Phytochemical and LC-MS Analysis, Antioxidant Properties, and Antimicrobial and Molecular Docking Analysis.","authors":"Zahid Ahmad Paul, Reyaz Hassan Mir, Aamir Tariq Malla, Mohd Adnan, Mitesh Patel, Reetesh Kumar, Shahid Ud Din Wani, Mohammed Iqbal Zargar, Mubashir Hussain Masoodi","doi":"10.1155/cjid/9925080","DOIUrl":"10.1155/cjid/9925080","url":null,"abstract":"<p><strong>Background: </strong><i>Achillea millefolium</i> L. (yarrow) is one of the oldest known medicinal plants recognized for properties, such as wound healing, fever, common cold, liver problems, nosebleeding, toothache, and headache. Yarrow, being native to Europe, grows wild in the whole of Asia, Northern Europe, and North America and also occurs wild in Kashmir.</p><p><strong>Objectives: </strong>This study aimed to investigate the antioxidant and antimicrobial properties of <i>Achillea millefolium</i> L. (AM), focusing on its ethanolic extract and its fractions (hexane and ethyl acetate).</p><p><strong>Methods: </strong>The antioxidant activity of the extracts was assessed using reducing power and DPPH radical scavenging assays. The extract and its fractions (hexane and ethyl acetate) were evaluated for antimicrobial activity by the agar well diffusion method. Additionally, LC-MS was employed to analyze the chemical composition of the ethyl acetate fraction, and molecular docking studies were conducted to understand its mechanisms of action.</p><p><strong>Results: </strong>The ethyl acetate fraction showed the highest antioxidant activity with an IC₅₀ value of 199.12 (μg/mL), antibacterial activity against <i>B. subtilis</i>, ZOI = 14.74 ± 0.16, and antifungal activity against <i>C. neoforman</i>s 34.70 ± 0.58. LC-MS identified key compounds, including diosmin, pelargonin, and epicatechin. From the docking analysis, the highest binding affinity was monitored in the cases of diosmin with -10.7 kcal, followed by pelargonin (-9.3 kcal) and epicatechin (-8.6 kcal) with the EF-TU complex protein.</p><p><strong>Conclusion: </strong>In summary, this study highlights the antioxidant and antimicrobial capabilities of <i>Achillea millefolium</i> L. These findings will establish the groundwork for bioassay-guided separation of bioactive components that could serve as leads for future research to combat diseases caused by microbes that are resistant to drugs.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2026 ","pages":"9925080"},"PeriodicalIF":2.4,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13288361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148320286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Clinical Profiles of <i>Bacteroides fragilis</i> Bacteremia in a Tertiary Care Setting: A 5-Year Review.","authors":"Meliha Çağla Sönmezer, Enes Erul, Nagihan Aka Türkmen, Taha Koray Sahin, Mervenur Demir Cuha, Gülşen Hazırolan, Murat Akova","doi":"10.1155/cjid/5844253","DOIUrl":"10.1155/cjid/5844253","url":null,"abstract":"<p><strong>Background: </strong>Anaerobic infections remain clinically significant yet underrecognized due to diagnostic challenges and limited routine susceptibility testing in clinical laboratories. Among these pathogens, <i>Bacteroides fragilis</i> is a clinically important anaerobe associated with bloodstream and deep-seated infections. This study aimed to evaluate the epidemiology, clinical characteristics, and antimicrobial resistance patterns of <i>Bacteroides fragilis</i> bacteremia in a tertiary care hospital.</p><p><strong>Materials and methods: </strong>This retrospective study included patients with blood cultures positive for <i>Bacteroides fragilis</i> between July 2018 and January 2023. Demographic characteristics, clinical features, infection sources, treatment regimens, and antimicrobial resistance patterns were analyzed.</p><p><strong>Results: </strong>Our analysis found a higher rate of <i>Bacteroides fragilis</i> bacteremia among cancer patients, likely linked to cancer treatments that compromise gastrointestinal defenses. Notably, both hospital-acquired infection (OR: 4.99, 95% CI: 1.3-19.07, <i>p</i> = 0.019) and respiratory tract infection (OR: 8.19, 95% CI: 1.21-55.35, <i>p</i> = 0.031) were associated with an increased risk of death within 30 days, highlighting the importance of vigilance in healthcare environments. Resistance to clindamycin was substantial, while ampicillin resistance was expected because of the intrinsic resistance profile of Bacteroides species. While carbapenem resistance was uncommon, its presence signals a shifting resistance pattern. Metronidazole remained effective, supporting its continued use.</p><p><strong>Conclusion: </strong><i>Bacteroides fragilis</i> bacteremia is associated with significant mortality, particularly in nosocomial settings. Continuous surveillance and appropriate antimicrobial stewardship are essential for effective management.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2026 ","pages":"5844253"},"PeriodicalIF":2.4,"publicationDate":"2026-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13284290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LAMP-Based Detection of <i>Candida albicans</i>: A Potential Tool for Candidemia Diagnosis.","authors":"Eakkapote Prompunt, Kannika Jamnai, Nawapol Marome, Nathaporn Phutthawong, Thitima Sumphanapai, Parin Kamseng, Chiraphat Kloypan, Somphot Saoin, Supaporn Khamchun, Sawitree Nangola","doi":"10.1155/cjid/1980977","DOIUrl":"10.1155/cjid/1980977","url":null,"abstract":"<p><p>Candidemia is a life-threatening bloodstream infection, most commonly caused by <i>Candida albicans</i> (<i>C. albicans</i>), and remains a significant concern in immunocompromised patients. Rapid and accurate species-level detection is essential for effective clinical management. Loop-mediated isothermal amplification (LAMP) is a robust nucleic acid amplification method that enables rapid pathogen detection under isothermal conditions. This study developed and evaluated an <i>ITS2</i>-targeted LAMP assay for the detection of <i>C. albicans</i> in human blood. Analytical sensitivity and specificity were assessed using tenfold serial dilutions of DNA from a standard <i>C. albicans</i> strain (1 ng-1 fg). Specificity was tested against six other fungal species commonly involved in bloodstream infections: <i>C. tropicalis</i>, <i>C. krusei</i>, <i>C. neoformans</i>, <i>Fusarium</i> spp., <i>Aspergillus flavus</i>, and <i>A. niger</i>. The assay detected <i>C. albicans</i> DNA at concentrations as low as 10 fg, surpassing conventional PCR, which detected down to 10 pg. No cross-reactivity was observed with non-albicans species tested. Performance in blood was evaluated using artificially spiked samples, in which the assay consistently detected <i>C. albicans</i> at 10¹ CFU/mL under controlled experimental conditions. These findings demonstrate that the <i>ITS2</i>-based LAMP assay provides a rapid and sensitive molecular approach for the detection of <i>C. albicans</i> under the experimental conditions evaluated and may have potential as a complementary tool for candidemia detection following further clinical validation.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2026 ","pages":"1980977"},"PeriodicalIF":2.4,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13281705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148297345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Assessment of Healthcare Professionals' and Students' Perspectives and Intentions for Raising Public Awareness and Comprehension of Antimicrobial Resistance\".","authors":"","doi":"10.1155/cjid/9785695","DOIUrl":"https://doi.org/10.1155/cjid/9785695","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/cjid/4106594.].</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2026 ","pages":"9785695"},"PeriodicalIF":2.4,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13270248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, Genetic Diversity, and Risk Factors of <i>Cryptosporidium</i> spp. in HIV/AIDS Patients: An Updated Systematic Review and Meta-Analysis (2017-2025).","authors":"Farzad Mahdavi, Mohammad Reza Mohammadi, Shayan Heidari, Roumina Norouzi, Ali Pouryousef, Kambiz Karimi, Asma Mousivand, Mahtab Mehboodi, Ali Asghari, Hassan Nourmohammadi","doi":"10.1155/cjid/2740716","DOIUrl":"10.1155/cjid/2740716","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;&lt;i&gt;Cryptosporidium&lt;/i&gt; spp. is a major opportunistic pathogens in HIV/AIDS patients, contributing substantially to morbidity and mortality worldwide. Despite advances in HIV/AIDS management, the global burden, genetic diversity, and risk factors of cryptosporidiosis in this high-risk group remain incompletely understood.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We conducted a systematic review and meta-analysis of cross-sectional and case-control studies published between January 1, 2017, and June 10, 2025, in accordance with PRISMA 2020 guidelines. Literature searches were performed in PubMed, Scopus, Embase, and Web of Science, supplemented by Google Scholar. Eligible studies reported the prevalence of &lt;i&gt;Cryptosporidium&lt;/i&gt; spp. in HIV/AIDS patients, with or without comparison groups, using microscopy, serology, or molecular methods. Data extraction was performed independently by two reviewers, and study quality was assessed using the JBI checklist. Random-effects models were applied in Comprehensive Meta-Analysis software, with subgroup analyses and meta-regression conducted to explore prevalence and heterogeneity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 89 studies were included. The pooled prevalence of &lt;i&gt;Cryptosporidium&lt;/i&gt; spp. among HIV/AIDS patients was 9.5% (95% CI: 7.6-11.8). Based on 17 case-control studies, HIV-positive individuals had a significantly higher risk of infection compared to HIV-negative controls (OR: 3.5, 95% CI: 2.1-5.9). Subgroup analyses revealed higher pooled prevalence in smaller studies, medium-HDI and lower-middle-income countries, and African and Central American settings. Pooled prevalence did not differ significantly across diagnostic methods. Among HIV/AIDS patients positive for &lt;i&gt;Cryptosporidium&lt;/i&gt; spp., 39.8% were aged ≤ 30 years and 64.7% were &gt; 30 years. Females represented 54.5% of positives, slightly higher than males at 45.8%. Most infected patients had CD4 counts ≤ 200 cells/μL (62.5%), compared to 43.2% with counts &gt; 200. Diarrhea was present in 78.4% of positive cases, versus 43.8% among those without infection. Meta-regression confirmed a significant inverse association between sample size and prevalence (&lt;i&gt;β&lt;/i&gt; = -0.0019, &lt;i&gt;p&lt;/i&gt; = 0.003). Molecular data identified diverse species and subtypes, with &lt;i&gt;C. hominis&lt;/i&gt; and &lt;i&gt;C. parvum&lt;/i&gt; predominating but zoonotic species such as &lt;i&gt;C. meleagridis&lt;/i&gt;, &lt;i&gt;C. felis&lt;/i&gt;, &lt;i&gt;C. viatorum&lt;/i&gt;, &lt;i&gt;C. canis&lt;/i&gt;, &lt;i&gt;C. suis&lt;/i&gt;, &lt;i&gt;C. andersoni&lt;/i&gt;, and &lt;i&gt;C. cuniculus&lt;/i&gt; also reported. Sensitivity analyses showed no single study significantly influenced the pooled prevalence. Funnel plot asymmetry and Egger's test indicated publication bias.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This updated synthesis demonstrates that cryptosporidiosis remains a substantial health burden in HIV/AIDS patients, with notable genetic diversity reflecting both anthroponotic and zoonotic transmission routes. The strong association with immunosup","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2026 ","pages":"2740716"},"PeriodicalIF":2.4,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148254338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Diabetes Mellitus on the Development of Multidrug-Resistant Tuberculosis (MDR-TB) in Relation With Genetic Mutations of <i>M. tuberculosis</i> Isolates in Ethiopia.","authors":"Aynias Seid, Semira Nureddin","doi":"10.1155/cjid/7830270","DOIUrl":"10.1155/cjid/7830270","url":null,"abstract":"<p><p>In nations with developing healthcare infrastructures, the dual burden of Type 2 diabetes mellitus (T2DM) and tuberculosis represents a critical health challenge. The aim of this study is to investigate the influence of T2DM on the development of multidrug-resistance tuberculosis (MDR-TB) in relation to genetic mutations of <i>Mycobacterium tuberculosis</i> in Ethiopia. A facility-based cross-sectional study was carried out between 2023 and 2024. Genetic mutations associated with drug resistance in both diabetic and nondiabetic groups were detected using line probe assays (LPAs). Diagnosis of T2DM was performed using fasting blood glucose and glycated hemoglobin levels. Data were analyzed with SPSS software, and logistic regression models were performed. Our findings revealed that 44 of the 182 participants (24.2%) were TB-T2DM, whereas 138 (75.8%) were TB with nondiabetic groups. Multivariate analysis displayed that the prior TB treatment history (aOR: 2.51, 95%CI: 1.02-6.19, <i>p</i> = 0.046) and a family history of T2DM (aOR: 2.25, 95% CI: 1.10-4.60, <i>p</i> = 0.031) were independently associated with an increased risk of TB-T2DM comorbidity. Genetic analysis identified a total of 50 mutations (22 <i>rpoB</i>, 22 <i>katG</i>, and 6 <i>inhA</i> promoter) associated with resistance to RIF and INH drugs among 31 drug-resistant <i>M. tuberculosis</i> isolates, which were significantly more common in TB-T2DM comorbid patients (<i>p</i> = 0.009). The <i>rpoB</i> S450L and <i>katG</i> S315T1 were the predominant mutations typically associated with high-level RIF and INH resistance, respectively, and high biological fitness, allowing for successful transmission within the community. Among the dual mutations identified in MDR-TB isolates, only the <i>rpoB</i> UN + <i>katG</i> S315T1 mutation was significantly more prevalent in nondiabetics (<i>p</i> = 0.04) compared to the TB-T2DM comorbid group. Multivariate analysis revealed that prior TB treatment history (aOR: 4.00, 95% CI: 1.31-12.50, <i>p</i> = 0.014) and TB-T2DM comorbidity (aOR: 3.12, 95% CI: 1.02-9.10, <i>p</i> = 0.042) were significantly associated with an increased likelihood of MDR-TB. This increased odd of resistance in comorbid patients highlights the need for bidirectional T2DM screening for all TB patients, particularly those with a history of prior TB treatment or a family history of diabetes. A genome-wide association study into the mutation patterns responsible for DR is crucial to inform the development of targeted, effective strategies moving forward.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2026 ","pages":"7830270"},"PeriodicalIF":2.4,"publicationDate":"2026-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13239177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148200940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonantibiotic Treatment of Clinical Multidrug-Resistant Bacterial Isolates Using Chitosan Nanoparticles as a Carrier for the Supernatant of Mesenchymal Stem Cells.","authors":"Sareh Bagheri-Josheghani, Mahmood Saffari, Hamed Mirzaei, Zahra Sadat Fateminasab, Mozhgan Derakhshan-Sefidi, Somaye Rashki, Bita Bakhshi","doi":"10.1155/cjid/3465372","DOIUrl":"10.1155/cjid/3465372","url":null,"abstract":"<p><p>This study aimed to evaluate the antimicrobial potential of the supernatant (conditioned medium) of mesenchymal stem cells-derived conditioned medium (MSCs CM), incorporated in chitosan nanoparticles (CS NPs), against multidrug-resistant (MDR) clinical isolates. Dynamic light scattering (DLS), zeta potential (ZP), and scanning electron microscopy (SEM) assays were used to characterize CS NPs. MSCs CM was incorporated into CS NPs, and its release pattern from the composite (MSCs CM-CS NPs) was evaluated. Antibacterial properties of MSCs CM-CS NPs, as well as MSCs CM and CS NPs, were assessed by the microbroth dilution technique. The average particle size of most CS NPs was 85.2 nm, and their zeta potential was 32.1 mV. SEM findings supported the morphology of the prepared CS NPs and the synthesized composite (MSCs CM-CS NPs). Entrapment efficiency of the new construct was 71%. The antimicrobial activity of the new construct (MSCs CM-CS NPs: 1000 μg/mL + 0.05%) against MDR bacteria was significantly higher compared with MSCs CM (1000 μg/mL) and CS NPs (0.05%) each alone. This composite exhibited the synergistic antibacterial activity of the combination of MSCs CM and CS NPs, resulting in a more potent dose-dependent antibacterial activity against MDR clinical isolates.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2026 ","pages":"3465372"},"PeriodicalIF":2.4,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13216856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148139437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Comprehensive Global Bibliometric Analysis of Monkeypox Virus Research Landscape From 1976 to 2025.","authors":"Uwem Okon Edet, Md Zulfekar Ali, Bassey Ini Ubi, Edema Enogiomwan Imalele, Bassey Edet, Francisca Nwaokorie, Clement Meseko","doi":"10.1155/cjid/2362823","DOIUrl":"10.1155/cjid/2362823","url":null,"abstract":"<p><strong>Background: </strong>Six decades have elapsed since the index case of monkeypox virus (MPXV) was reported. Unlike most DNA viruses characterized by slow mutation and spread, MPXV caused the global outbreak of 2022, and as expected, several studies prior and post the 2022 outbreak have emanated. Despite its ability to trigger a potential pandemic, there is no holistic quantitative and qualitative insight into MPXV research landscape globally.</p><p><strong>Methods: </strong>Following the Scientific Procedures and Rationales for Systematic Literature Review (SPAR-4-SLR protocol) applied to the Scopus database, studies were retrieved covering 1976-2025 on MPXV globally and screened using predefined criteria. The final dataset was analyzed using Biblioshiny, RStudio, and VOSviewer tool.</p><p><strong>Results: </strong>Of the 8460 retrieved records, 5315 met the inclusion and exclusion criteria, comprising 79.98% original articles and 20.02% review articles, authored by 32,098 researchers across 1547 journals. Our analysis of the MPXV research revealed an average annual growth rate of 12.38%, with a pronounced surge after 2021, coinciding with the global 2022 outbreak. The United States dominated research output, authorship, funding, institutional leadership, and international collaborations, with the Centers for Disease Control (CDC) emerging as the most influential institution. China, India, and the United Kingdom also contributed substantially, while resource-poor settings were underrepresented. Keyword and thematic analyses revealed a transition from early virological and animal studies to recent emphasis on human transmission, epidemiology, vaccination, and therapeutics. Highly cited studies were concentrated in leading infectious disease journals. Overall, MPXV research has evolved rapidly, highlighting expanding global collaboration and shifting research priorities.</p><p><strong>Conclusion: </strong>The study demonstrates a sharp post-2021 expansion of MPXV research, dominated by high-income countries, particularly the United States. Strengthening research contributions, surveillance, and collaborations from MPXV-endemic regions in Africa is essential for balanced global preparedness and response efforts.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":"2026 ","pages":"2362823"},"PeriodicalIF":2.4,"publicationDate":"2026-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13199685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148037383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}